| Literature DB >> 31445891 |
Eva Yus1, Verónica Lloréns-Rico2, Sira Martínez3, Carolina Gallo3, Hinnerk Eilers4, Cedric Blötz4, Jörg Stülke4, Maria Lluch-Senar3, Luis Serrano5.
Abstract
Here, we determined the relative importance of different transcriptional mechanisms in the genome-reduced bacterium Mycoplasma pneumoniae, by employing an array of experimental techniques under multiple genetic and environmental perturbations. Of the 143 genes tested (21% of the bacterium's annotated proteins), only 55% showed an altered phenotype, highlighting the robustness of biological systems. We identified nine transcription factors (TFs) and their targets, representing 43% of the genome, and 16 regulators that indirectly affect transcription. Only 20% of transcriptional regulation is mediated by canonical TFs when responding to perturbations. Using a Random Forest, we quantified the non-redundant contribution of different mechanisms such as supercoiling, metabolic control, RNA degradation, and chromosome topology to transcriptional changes. Model-predicted gene changes correlate well with experimental data in 95% of the tested perturbations, explaining up to 70% of the total variance when also considering noise. This analysis highlights the importance of considering non-TF-mediated regulation when engineering bacteria.Entities:
Keywords: Mycoplasma pneumoniae; gene regulatory network; systems biology; transcription; transcription factors; transcription regulation
Mesh:
Substances:
Year: 2019 PMID: 31445891 PMCID: PMC6721554 DOI: 10.1016/j.cels.2019.07.001
Source DB: PubMed Journal: Cell Syst ISSN: 2405-4712 Impact factor: 10.304
Figure 1Schematic Definition of the Workflow to Determine the Mycoplasma pneumoniae Gene Regulatory Network
Figure 2ChIP-Seq Results for Validating DNA Binding
ChIP-seq selected tracks for different proteins: TFs, RNAP complex, structural, and proteins involved in DNA replication, as well as DNA regions protected from DNase digestion (POD). Vertical lines indicate annotated TSSs and the origin of replication region (OriC). The regions or peaks bound by the studied protein or protected from DNase digestion are shown in the color of the corresponding category. The x axis shows the base position in the genome. The y axis shows the read coverage per base. Binding motifs found for some of the structural proteins are shown in the right.
Figure 3Classification of the Candidates and DNA Motifs Using the Phenotypic Analyses
(A) The sequence motifs for 9 TFs analyzed in this study (in orange hexagons), as well as their main regulated targets (arrows indicate activation and crosses repression) are shown. We also show the proteins identified as regulators in this study (orange diamonds) and the functional category of the genes they significantly affected (if a regulator affects a single gene in a functional category, we do not show it; see Table S5).
(B) M. pneumoniae phenotypes. Experiments were classified into three groups according to the number of identified transcriptional changes that they displayed. For each group, bar charts show the percentage of genes that display a growth curve phenotype (faster or slower growth and/or medium acidification) with respect to the total.
(C) Inferelator results on the genetic perturbations. The Venn diagram depicts the interactions retrieved manually, those found using Inferelator, and those common to both methods.
(D) Network of the transcriptional phenotypes induced by OE, KO and/or mutants of all genes selected in this study, as well as by environmental perturbations. Lines represent correlations between the experiments above 0.45. Colors represent different clusters of highly interconnected experiments. Clusters enriched in different functional categories are represented in shaded circles. Perturbations are shown in square boxes and overexpressed, mutated or deleted genes in ovals. The sign of fresh medium addition was reversed for visualization in the growth-associated cluster (with which it correlates negatively).
Figure 4Network of Co-regulated Genes in M. pneumoniae
(A) Network of co-expressed genes in M. pneumoniae. Nodes of the network represent genes, and the edges between two nodes indicate co-expression (r > 0.5). Colors of the network nodes represent different clusters of highly interconnected genes (i.e., highly co-expressed). We show the functional categories significantly enriched in each group (Benjamini-Hochberg adjusted p < 0.05). Inset shows the two main expression clusters determined by k-means clustering analysis.
(B) TFs partly explain some of the different clusters of co-regulated genes. Genes targeted by different TFs are marked with different colors.
(C) Transcriptional changes induced by the Ldh and MPN294 (disulfide chaperone) genes are, in the case of upregulation (blue nodes), mainly explained by the DnaA TF and involve genes related to nucleotide metabolism. Red nodes indicate downregulated genes.
(D) Supercoiling driven by heat or cold shock explain the two major clusters of co-regulated genes. Blue nodes: genes upregulated in cold shock and downregulated in heat shock. Red nodes: genes downregulated in cold shock and upregulated in heat shock.
(E) An initial GC dinucleotide at the TSS (blue nodes) explains a large part of the ribosome-associated cluster.
Results of the Random Forest Model for Each Experimental Condition Studied
| Experiment | Adjusted R2 (Variance Explained) | Spearman Correlation (Predicted versus Real) |
|---|---|---|
| Thioguanine | 0.533 | 0.775 |
| Sanguinarine | 0.454 | 0.719 |
| Fresh media | 0.500 | 0.717 |
| Thiolutin | 0.418 | 0.680 |
| Chloramphenicol | 0.498 | 0.678 |
| Osmostress | 0.507 | 0.679 |
| Mitomycin C | 0.489 | 0.687 |
| Norfloxacin | 0.550 | 0.673 |
| Macrolides | 0.510 | 0.683 |
| Glycerol | 0.455 | 0.656 |
| Growth | 0.546 | 0.660 |
| Tetracyclines | 0.467 | 0.645 |
| Cytochalasin B | 0.478 | 0.594 |
| Spectinomycin | 0.425 | 0.601 |
| Puromycin | 0.505 | 0.665 |
| Gencitabine | 0.338 | 0.556 |
| Peroxide | 0.365 | 0.591 |
| Shx | 0.423 | 0.563 |
| CCCP | 0.352 | 0.565 |
| Norvalin | 0.520 | 0.562 |
| Triton X | 0.405 | 0.571 |
| pH 6 | 0.281 | 0.536 |
| Bipyridine | 0.253 | 0.422 |
Figure 5Variance Explained in Experimental Perturbations
(A) The upper panel shows correlation plots between the predicted and the experimental fold changes for three different perturbations: entry into stationary phase, glycerol, and thioguanine addition. The lower panel shows the variance explained by each canonical or alternative mechanism for these experiments.
(B) The violin plots show, for each experiment, how much variance (in %) can be explained by each regulatory mechanism. The total variance explained in the entire dataset (not accounting for noise) is 45%.
Figure 6Cellular Processes and Their Respective Regulatory Mechanisms
(A) A simplified version of the gene regulatory network of M. pneumoniae, incorporating both canonical and alternative regulatory mechanisms. Different cellular processes preferentially use one regulatory mechanism over another to control the expression of genes.
(B) Simplified schema of the structural proteins and their binding regions in the chromosome of M. pneumoniae.
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Anti-Flag Monoclonal Antibody | Sigma | Cat#F3165; RRID: |
| Colleague | Richard Herrmann | |
| this paper | Mendeley: [doi: | |
| 6-Thioguanine | Sigma | Cat#A4882 |
| Azithromycin | Sigma | Cat#75199 |
| CCCP | Sigma | Cat#C2759 |
| Ciprofloxacin | Sigma | Cat#17850 |
| Clarythromycin | Sigma | Cat#C9742 |
| Cytochalasin B | Sigma | Cat#C8273 |
| DCCD | Sigma | Cat#D80002 |
| Diamide | Sigma | Cat#D3648 |
| Doxycycline | Sigma | Cat#D9891 |
| Erythromycin | Sigma | Cat#E5389 |
| Gemcitabine | Sigma | Cat#G6423 |
| Levofloxacin | Sigma | Cat#28266 |
| Minocycline | Sigma | Cat#M9511 |
| Mitomycin C | Sigma | Cat#M4287 |
| Norfloxacin | Sigma | Cat#N9890 |
| Plasmocin | Invivogen | Cat#ant-mpp |
| Pyocyanin | Sigma | Cat#P0046 |
| Sanguinarine | Sigma | Cat#S5890 |
| Spectinomycin | Sigma | Cat#S4014 |
| Spiramycin | Sigma | Cat#S9132 |
| Streptomycin | Sigma | Cat#S6501 |
| T-butyl hydroperoxide | Sigma | Cat#458139 |
| Tetracycline | Sigma | Cat#T3258 |
| Thiolutin | Fermentek | Cat#87-11-6 |
| Valinomycin | Sigma | Cat#V0627 |
| NebNExt Ultra kit | New England Biolabs | Cat#E7370L |
| RNA Isolation Kit: RNeasy Mini Kit | Qiagen | Cat#74004 |
| TruSeq smallSmall RNA Sample Prep Kit | Illumina | Cat#RS-200-0012 |
| Phosphopeptide Enrichment kit | Thermo Scientific | Cat#88301 |
| RNA-Seq: Phenome analysis of Mycoplasma pneumoniae | this paper | ArrayExpress |
| RNA-seq: Transcriptome analysis of Mycoplasma pneumoniae I | this paper | ArrayExpress |
| RNA-seq: Transcriptome analysis of Mycoplasma pneumoniae III | this paper | ArrayExpress |
| DNase proteccion: Protein occupancy of Mycoplasma pneumoniae chromosome | this paper | ArrayExpress |
| RNA-seq: Transcriptome analysis of Mycoplasma pneumoniae IV | this paper | ArrayExpress |
| ChIP-seq of Mycoplasma pneumoniae putative Transcription factors | this paper | ArrayExpress |
| RNA-seq: 5'′-end mapping of totalTotal Mycoplasma pneumoniae RNA | this paper | ArrayExpress |
| RNA-seq: Transcriptome analysis of Mycoplasma pneumoniae V | this paper | ArrayExpress |
| RNA-seq: Transcriptome analysis of Mycoplasma pneumoniae VI | this paper | ArrayExpress |
| Proteomics: Mycoplasma pneumoniae Chromatin isolation | this paper | ProteomeXchange XD007672 |
| Proteomics: DNA Affinity chromatography on Mycoplasma pneumoniae extracts I (RNA elution) | this paper | ProteomeXchange |
| Proteomics: DNA Affinity chromatography on Mycoplasma pneumoniae extracts II (cellulose column) | this paper | ProteomeXchange |
| Proteomics: DNA Affinity chromatography on Mycoplasma pneumoniae extracts III (DNA column) | this paper | ProteomeXchange |
| Proteomics: TF overexpression and mutant data | this paper | ProteomeXchange |
| Oligonucleotides | this paper | Mendeley: [doi: |
| Plasmids | this paper | Mendeley: [doi: |
| Xcalibur software v3.0.63 | Thermo Fisher Scientific | |
| Proteome Discoverer software suite v2.0 | Thermo Fisher Scientific | |
| MAQ software | N/A | |
| Inferelator software | ||
| R version 3.5.1 | R Core Team, 2018 | |
| tidyverse (R packages ; version 1.2.1) | R package | |
| ggpubr (R package ; version 0.2) | R package | |
| Gdata (R package ; version 2.18.0) | R package | |
| DESeq2 (R package ; version 1.22.2) | R package | |
| NbClust (R package ; version 3.0) | R package | |
| randomForest (R package ; version 4.6-14) | R package | |
| Cytoscape (Version 3.6.0) | ||
| clusterMaker2 (Cytoscape plugin, version 1.2.1) | Cytoscape plugin | |
| Treatment | Perturbant | Concentration | Duration (min) |
|---|---|---|---|
| G metabolism | 6-Thioguanine 200 μg ml-l | 30 | |
| Protein synthesis inhibition | Azithromycin 0.0078 μg ml-1 | 60 | |
| PMF uncoupler | CCCP | 2 mM | 30 |
| Protein synthesis inhibition | Chloramphenicol 20 μg ml-1 | 60 | |
| DNA damage | Ciprofloxacin 1 μg ml-1 | 60 | |
| Protein synthesis inhibition | Clarythromycin | 0.015 μg ml-1 | 60 |
| Cell cycle | Cytochalasin B | 75 μg ml-1 | 60 |
| PMF | DCCD | 0.4 mM | 60 |
| Redox balance | Diamide 1 mM | 30 | |
| Protein synthesis inhibition | Doxycycline 0.3 μg ml-1 | 60 | |
| Protein synthesis inhibition | Erythromycin 0.0156μg ml-1 | 60 | |
| G metabolism | Gemcitabine 50 μg ml-1 | 30 | |
| Oxidative stress | Hydrogen peroxide | 0.1% | 20 |
| Oxidative stress | Hydrogen peroxide | 0.5% | 20 |
| DNA damage | Levofloxacin 0.75 μg ml-1 | 60 | |
| Protein synthesis inhibition | Minocycline 0.3 μg ml-1 | 60 | |
| DNA damage | Mitomycin C 5 μg ml-1 | 60 | |
| DNA damage | Mitomycin C 0.5 μg ml-1 | 60 | |
| DNA damage | Norfloxacin 10 μg ml-1 | 60 | |
| DNA gyrase | Plasmocin | 1 μg ml-1 | 60 |
| Oxidative stress | Pyocyanin | 3 μg ml-1 | 60 |
| FtsZ inhibitor | Sanguinarine | 28 μM | 60 |
| Protein synthesis inhibition | Spectinomycin 5 μg ml-1 | 60 | |
| Protein synthesis inhibition | Spiramycin 0.5 μg ml-1 | 60 | |
| Protein synthesis inhibition | Streptomycin 5 μg ml-1 | 60 | |
| Oxidative stress | T-butyl hydroperoxide 0.1 mM | 60 | |
| Protein synthesis inhibition | Tetracycline 0.3 μg ml-1 | 60 | |
| RNAP inhibitor/Zn2+ chelator | Thiolutin | 2.5 μg ml-1 | 60 |
| Membrane integrity | Triton X-100 | 0.01% | 60 |
| Potassium ionophore | Valinomycin | 0.1 mM | 60 |
PMF: Proton motive force